Second Quarter Report Q2-2024
The Company has advanced well with its planned activities · First patient dosed in Paediatric Safety Study 0202 · Superior simulated pain efficacy in children with CT001 · New member of the Board of Directors, Anders Dyhr D-Toft · US launch finalization and final approvals still ongoing...Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 April – 30 June 2024. The second quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports. Second quarter financial results